Lifeboat Foundation

Robotmaker Boston Dynamics has finally put its four-legged robot Spot on general sale. After years of development, the company began leasing the machine to businesses last year, and, as of today, is now letting any US firm buy their very own Spot for $74,500.

It’s a hefty price tag, equal to the base price for a luxury Tesla Model S. But Boston Dynamics says, for that money, you’re getting the most advanced mobile robot in the world, able to go pretty much anywhere a human can (as long as there are no ladders involved).

Continue reading “Boston Dynamics will now sell any business its own Spot robot for $74,500” »

Dexamethasone, a cheap and widely used steroid, has become the first drug shown to be able to save lives among Covid-19 patients in what scientists hailed as a “major breakthrough”.

Results of trials announced on Tuesday showed dexamethasone, which is used to reduce inflammation in other diseases, reduced death rates by around a third among the most severely ill Covid-19 patients admitted to hospital.

The results suggest the drug should immediately become standard care in patients with severe cases of the pandemic disease, said the researchers who led the trials.

If only we had working longevity/aging reversal science now.

People under the age of 20 are half as likely to contract COVID-19 than the rest of the population, according to new modeling released on Tuesday that suggests four out of five infected young people show no symptoms.

The research, published in the Nature Medicine Journal, could help inform the next moves of governments under pressure to reopen schools and colleges shuttered since the start of the pandemic.

Continue reading “Under-20s half as likely to contract coronavirus: study” »

Researchers in England say they have the first evidence that a drug can improve COVID-19 survival: A cheap, widely available steroid reduced deaths by up to one third in severely ill hospitalized patients.

The results were announced Tuesday and the British government immediately authorized the drug’s use across the United Kingdom for coronavirus patients like those who did well in the study. Researchers said they would publish results soon, and several independent experts said it’s important to see details to know how much of a difference the drug, dexamethasone, might make and for whom.

But “bottom line is, good news,” said the United States’ top infectious disease expert, Dr. Anthony Fauci. “This is a significant improvement in the available therapeutic options that we have.”

A pair of researchers at University College London has found that people with low socioeconomic status experience more declines in age-related functions as they grow older than do people who have a higher socioeconomic status. In their paper published in Proceedings of the National Academy of Sciences, Andrew Steptoe and Paola Zaninotto describe their study of data from the English Longitudinal Study of Ageing, and what they learned.

Prior research has shown that poor people tend to suffer more adverse health effects than those who are better off. They also tend to die younger. But one area of aging that has not been well-studied is the impact of poverty on age-related functional decline, associated with such symptoms as loss of hearing or muscle strength. To learn more about the relationship between socioeconomic status and age-related functional decline, the researchers analyzed data in the English Longitudinal Study of Ageing—an ongoing long-term study of the aging process. Launched in 2002, the study involved collecting data on volunteers aged 50 and over as they grew older. The data includes both medical and physical information, along with test results designed to measure cognitive and emotional levels. The data sample for this new effort included information on 5,018 people 52 years of age or older as they aged over periods of six to eight years.

The researchers found that people living at the lower end of the economic spectrum performed worse on every measure of age-related functionality. Those less well-off lost grip strength, lung function, gait speed, processing speed and executive function. They also tended to report enjoying life less than those who were more affluent. The researchers noted their findings were independent of race, gender, education or age. They also found that those of lesser means experienced more vision problems and were more likely to be depressed.

Sending a handful of people certainly could serve as a proof of concept analogous to America’s Spanish and Portuguese outposts in the early 1500’s, or the English and Dutch settlements in the early 1600’s. In these instances the populations measured in the dozens and would not have amounted to a lasting European presence had they not been followed by thousands of new settlers over the next few decades. But, given our more advanced technology, our level of medicine, the idea that humans could have equipment that will utilize the Martian environment to produce food, air, and other consumables, and the certainty that settlers will not be at war with the Martian equivalent of the Aztecs or Incas—couldn’t a Martian settlement survive long term with just a low number of colonists?

The answer is no—not if the goal is a permanent human presence. Not if the goal is to provide our species with some kind of extinction insurance against planetary disaster on Earth, such as a mega-volcanic eruption, nuclear war, or some other existential threat. Mars setters can use technology to get air and food from the Mars environment, but early European explorers in the New World had access to one natural resource that mid-21st century Mars colonists will not be able to manufacture: a human gene pool.

If we really want Martian colonies, we can’t send just a few Adams and Eves. We can’t set-up a Martian Jamestown of 100 people. Long-term survival will depend on the genetic diversity of a large gene pool, and this means the Elon Musk plan of sending thousands might be the only colonization plan that could work.

There’s nothing small about the impact small businesses have on local communities. They turn towns into hometowns and strangers into neighbors.

And right now, they need our support.

Continue reading “Small Business Live” »

UK experts say the low-dose steroid treatment is a major breakthrough in the fight against the deadly virus.

It cut the risk of death by a third for patients on ventilators. For those on oxygen, it cut deaths by a fifth.

The drug is part of the world’s biggest trial testing existing treatments to see if they also work for coronavirus.

Continue reading “Coronavirus: Dexamethasone proves first life-saving drug” »

In 2005, University of California, Berkeley, researchers made the surprising discovery that making conjoined twins out of young and old mice—such that they share blood and organs—can rejuvenate tissues and reverse the signs of aging in the old mice. The finding sparked a flurry of research into whether a youngster’s blood might contain special proteins or molecules that could serve as a “fountain of youth” for mice and humans alike.

But a new study by the same team shows that similar age-reversing effects can be achieved by simply diluting the blood plasma of old mice—no young blood needed.

In the study, the team found that replacing half of the blood plasma of old mice with a mixture of saline and albumin—where the albumin simply replaces protein that was lost when the original blood plasma was removed—has the same or stronger rejuvenation effects on the brain, liver and muscle than pairing with young mice or young blood exchange. Performing the same procedure on young mice had no detrimental effects on their health.